Israel “Izzy” Englander isn’t afraid to go against the market on TEVA, VRX and ACAD.
One of Wall Street’s best performing analysts sees strong long-term care growth for ACAD’s Nuplazid.
J.P.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its unaudited financial results for the third quarter ended September 30, 2017.
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) tumbled nearly 9% in Monday’s trading session, after the drug maker announced the presentation of data from the …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced the presentation of data from the Phase II -019 Study of pimavanserin in Alzheimer’s disease psychosis at the …
ACAD receives BTD in dementia-related psychosis; Initiates DRP phase 3 trial; Phase 2 SERENE trial discontinued.
Investors are pricing in some optimism in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), after the drug maker announced that the FDA has granted Breakthrough Therapy Designation to …